This is an abbreviated version of BT Catalyst. The full newsletter will return next week on Thursday.
FROM OUR WEB SITE
From Our Web Site
Greer Launches Phase III Trial for Oral Allergy Immunotherapy
Greer has launched a Phase III trial for sublingual-oral immunotherapy (SLIT) for adults with rhinoconjunctivitis caused by short ragweed pollen. The goal of the trial is to bring the use of oral immunotherapy to the U.S.
Duke Marine Lab Gets $1M for Molecular Biology Prof
A chair in molecular biology will be created at the Duke Marine Lab in Beaufort.
Metabolon To Collaborate On Insulin Resistance Study
Metabolon, Inc. is partnering with the European Group for the Study of Insulin Resistance (EGIR) to accelerate pre-diabetes diagnosis development. Metabolon will analyze a large number of samples taken by EGIR in European clinical trials.
Targacept Begins Clinical Trial for Depression Disorder
Targacept, Inc. has initiated a Phase 1 clinical trial for an augmentation therapy drug (TC-5214 ) to treat major depressive disorder (MDD).
Greer Reports Favorable Results for Oral Allergy Immunotherapy
Greer reports favorable results from a clinical trial testing the safety and tolerability of orally administering immunotherapy products (sublingual-oral immunotherapy).
BD to Expand in NC
BD plans a $134.7 million expansion in North Carolina over the next five years. It will build a new plant in Wilson County and expand operations in Durham County, for a total of a 274 new jobs.
Registration Open for Summer Educator Workshops
The 21st year of Biotechnology Center summer workshops includes five introductory and three special topics workshops across the state.
Ercole Biotech Acquired by AVI Biopharma
Ercole Biotech is acquired by AVI Biopharma
Biotech Leaders Look to the Future
Five biotechnology industry leaders discuss the state of biotechnology in North Carolina, recorded in a 60-minute podcast.
Salix Buys GI Products from German Drug Maker
Raleigh-based Salix Pharmaceuticals has purchased rights to several gastrointestinal disease therapies from Dr. Falk Pharma
New b3bio Joins Hamner Institute
B3Bio, a biotechnology company founded in 2007 with an expertise in RNA therapeutics, has joined The Hamner Institutes for Health Sciences business incubator in Research Triangle Park.
The full version of BT Catalyst will return next week. See the lastest news and events on our Web site.
This newsletter was sent Friday Mar. 21, 2008. You can manage your subscription online or respond to this e-mail.